Literature DB >> 29408820

Heterogeneity of Thyroid Cancer.

Ewa Chmielik1, Dagmara Rusinek2, Malgorzata Oczko-Wojciechowska2, Michal Jarzab3, Jolanta Krajewska2, Agnieszka Czarniecka4, Barbara Jarzab2.   

Abstract

There are 5 main histological types of thyroid cancers (TCs): papillary, follicular (also known as differentiated), poorly differentiated, anaplastic (the most aggressive form), and medullary TC, and only the latter arises from thyroid C cells. These different forms of TCs show significant variability, both among and within tumours. This great variation is particularly notable among the first 4 types, which all originate from thyroid follicular cells. Importantly, this heterogeneity is not limited to histopathological diversity only but is also manifested as variation in several genetic and/or epigenetic alterations, the numbers of interactions between the tumour and surrounding microenvironment, and interpatient differences, for example. All these factors contribute to the great complexity in the development of a tumour from cancer cells. In the present review, we summarise the knowledge accumulated about the heterogeneity of TCs. Further research in this direction should help to gain a better understanding of the underlying mechanisms contributing to the development and diversity of TCs, paving the way toward more effective treatment strategies.
© 2018 S. Karger AG, Basel.

Entities:  

Keywords:  BRAF mutation; Heterogeneity; RAS mutation; Thyroid cancer

Mesh:

Substances:

Year:  2018        PMID: 29408820     DOI: 10.1159/000486422

Source DB:  PubMed          Journal:  Pathobiology        ISSN: 1015-2008            Impact factor:   4.342


  35 in total

Review 1.  Multikinase inhibitors in thyroid cancer: timing of targeted therapy.

Authors:  Matti L Gild; Venessa H M Tsang; Roderick J Clifton-Bligh; Bruce G Robinson
Journal:  Nat Rev Endocrinol       Date:  2021-02-18       Impact factor: 43.330

2.  Exploring the correlation analysis of immune microenvironment, mutation burden and prognosis of papillary thyroid carcinoma based on Estimate algorithm.

Authors:  Ying Wang; Ying He; Liubin Cao; Xiaoqing Peng; Zhenyong Gu; Jun Yan
Journal:  Gland Surg       Date:  2022-05

3.  Copy Number Alterations in Papillary Thyroid Carcinomas: Does Loss of SESN2 Have a Role in Age-related Different Prognoses?

Authors:  Deise Cibele N DE Almeida; Michel Platini Caldas DE Souza; Carolina Koury Nassar Amorim; Jersey Heitor DA Silva MauÉs; Fernanda DO E Santo Sagica; Caroline Aquino Moreira-Nunes; Edivaldo Herculano C DE Oliveira
Journal:  Cancer Genomics Proteomics       Date:  2020 Sep-Oct       Impact factor: 4.069

4.  The pseudogene problem and RT-qPCR data normalization; SYMPK: a suitable reference gene for papillary thyroid carcinoma.

Authors:  Seyed-Morteza Javadirad; Mohammad Mokhtari; Ghazal Esfandiarpour; Mohsen Kolahdouzan
Journal:  Sci Rep       Date:  2020-10-27       Impact factor: 4.379

Review 5.  Intratumoral Heterogeneity in Differentiated Thyroid Tumors: An Intriguing Reappraisal in the Era of Personalized Medicine.

Authors:  Antonio Ieni; Roberto Vita; Cristina Pizzimenti; Salvatore Benvenga; Giovanni Tuccari
Journal:  J Pers Med       Date:  2021-04-23

Review 6.  Thyroid Carcinoma: Phenotypic Features, Underlying Biology and Potential Relevance for Targeting Therapy.

Authors:  Jinwei Hu; Isabella J Yuan; Saied Mirshahidi; Alfred Simental; Steve C Lee; Xiangpeng Yuan
Journal:  Int J Mol Sci       Date:  2021-02-16       Impact factor: 5.923

7.  MiR-6838-5p facilitates the proliferation and invasion of renal cell carcinoma cells through inhibiting the DMTF1/ARF-p53 axis.

Authors:  Xiaoqiang Zhai; Yan Wu; Dong Zhang; Hecheng Li; Tie Chong; Jun Zhao
Journal:  J Bioenerg Biomembr       Date:  2021-03-08       Impact factor: 2.945

8.  Prospective Analysis of TERT Promoter Mutations in Papillary Thyroid Carcinoma at a Single Institution.

Authors:  Yun-Suk Choi; Seong-Woon Choi; Jin-Wook Yi
Journal:  J Clin Med       Date:  2021-05-18       Impact factor: 4.241

9.  MiR-181a-5p Regulates NIS Expression in Papillary Thyroid Carcinoma.

Authors:  Wojciech Gierlikowski; Katarzyna Broniarek; Łukasz Cheda; Zbigniew Rogulski; Marta Kotlarek-Łysakowska
Journal:  Int J Mol Sci       Date:  2021-06-04       Impact factor: 5.923

10.  The Efficacy and Safety of Radiofrequency Ablation for Bilateral Papillary Thyroid Microcarcinoma.

Authors:  Lin Yan; Mingbo Zhang; Qing Song; Jing Xiao; Ying Zhang; Yukun Luo
Journal:  Front Endocrinol (Lausanne)       Date:  2021-06-11       Impact factor: 5.555

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.